Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatic Neoplasms | 38 | 2024 | 5444 | 2.300 |
Why?
|
Deoxycytidine | 9 | 2020 | 886 | 1.190 |
Why?
|
Adenocarcinoma | 15 | 2024 | 6359 | 1.090 |
Why?
|
Carcinoma, Pancreatic Ductal | 11 | 2024 | 1757 | 0.960 |
Why?
|
Neuropilin-1 | 3 | 2014 | 90 | 0.910 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 28 | 2024 | 11872 | 0.890 |
Why?
|
Paclitaxel | 5 | 2023 | 1727 | 0.800 |
Why?
|
Albumins | 4 | 2023 | 578 | 0.740 |
Why?
|
Neoplasms | 16 | 2024 | 22350 | 0.620 |
Why?
|
Fluorouracil | 9 | 2024 | 1651 | 0.600 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2020 | 287 | 0.600 |
Why?
|
Diphenylamine | 2 | 2017 | 49 | 0.560 |
Why?
|
Phenylurea Compounds | 2 | 2019 | 533 | 0.530 |
Why?
|
Maximum Tolerated Dose | 9 | 2020 | 895 | 0.530 |
Why?
|
Immunoconjugates | 3 | 2021 | 976 | 0.510 |
Why?
|
Sirolimus | 2 | 2013 | 1540 | 0.500 |
Why?
|
GPI-Linked Proteins | 2 | 2020 | 472 | 0.490 |
Why?
|
Gastrointestinal Neoplasms | 4 | 2023 | 957 | 0.420 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2020 | 1245 | 0.410 |
Why?
|
Neoadjuvant Therapy | 9 | 2023 | 2902 | 0.410 |
Why?
|
Quinolines | 1 | 2018 | 769 | 0.400 |
Why?
|
Sulfonamides | 3 | 2024 | 1982 | 0.390 |
Why?
|
Recombinant Fusion Proteins | 1 | 2020 | 3738 | 0.380 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 478 | 0.370 |
Why?
|
Camptothecin | 2 | 2021 | 599 | 0.360 |
Why?
|
Antibodies, Monoclonal | 4 | 2018 | 9244 | 0.350 |
Why?
|
Protein Kinase Inhibitors | 7 | 2024 | 5690 | 0.350 |
Why?
|
Chemokine CXCL12 | 1 | 2012 | 457 | 0.350 |
Why?
|
Thymidylate Synthase | 1 | 2010 | 74 | 0.340 |
Why?
|
Antineoplastic Agents | 9 | 2020 | 13643 | 0.340 |
Why?
|
Liver Neoplasms | 4 | 2021 | 4353 | 0.330 |
Why?
|
Pyridines | 2 | 2019 | 2888 | 0.320 |
Why?
|
Angiogenesis Inhibitors | 3 | 2014 | 2057 | 0.320 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2013 | 616 | 0.320 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2018 | 2326 | 0.290 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2013 | 3607 | 0.290 |
Why?
|
Receptors, CXCR4 | 1 | 2012 | 729 | 0.290 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2019 | 5329 | 0.280 |
Why?
|
Neoplasm Staging | 11 | 2021 | 11218 | 0.270 |
Why?
|
Leucovorin | 6 | 2024 | 644 | 0.260 |
Why?
|
Biliary Tract Neoplasms | 2 | 2018 | 186 | 0.240 |
Why?
|
Aged | 40 | 2024 | 171343 | 0.240 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2823 | 0.230 |
Why?
|
Middle Aged | 43 | 2024 | 223257 | 0.220 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 3 | 2024 | 1762 | 0.220 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2012 | 2060 | 0.210 |
Why?
|
Enhancer Elements, Genetic | 1 | 2010 | 1363 | 0.210 |
Why?
|
Neoplasm, Residual | 2 | 2021 | 1012 | 0.210 |
Why?
|
Mice, Nude | 5 | 2024 | 3616 | 0.210 |
Why?
|
bcl-X Protein | 1 | 2024 | 412 | 0.200 |
Why?
|
Treatment Outcome | 20 | 2024 | 65273 | 0.200 |
Why?
|
Hypoalbuminemia | 1 | 2023 | 90 | 0.200 |
Why?
|
Benzimidazoles | 2 | 2018 | 862 | 0.200 |
Why?
|
Drug Administration Schedule | 5 | 2021 | 4853 | 0.200 |
Why?
|
Colorectal Neoplasms | 4 | 2024 | 6962 | 0.200 |
Why?
|
Humans | 78 | 2024 | 766766 | 0.200 |
Why?
|
Adult | 33 | 2024 | 223307 | 0.200 |
Why?
|
Rectal Neoplasms | 2 | 2021 | 1183 | 0.200 |
Why?
|
Coronary Vasospasm | 1 | 2022 | 81 | 0.190 |
Why?
|
Pyrimidinones | 1 | 2024 | 385 | 0.190 |
Why?
|
Collagen Type I | 1 | 2024 | 616 | 0.180 |
Why?
|
Colonic Neoplasms | 1 | 2013 | 2534 | 0.180 |
Why?
|
Aged, 80 and over | 18 | 2024 | 59550 | 0.180 |
Why?
|
Receptors, Lymphocyte Homing | 1 | 2001 | 141 | 0.180 |
Why?
|
Indolizines | 1 | 2020 | 29 | 0.180 |
Why?
|
Cyclic N-Oxides | 1 | 2020 | 71 | 0.180 |
Why?
|
Lymphoma | 2 | 2001 | 1900 | 0.180 |
Why?
|
Pyridinium Compounds | 1 | 2020 | 80 | 0.170 |
Why?
|
Male | 44 | 2024 | 364142 | 0.170 |
Why?
|
Immunosuppressive Agents | 1 | 2013 | 4215 | 0.170 |
Why?
|
Female | 46 | 2024 | 396520 | 0.170 |
Why?
|
Piperidines | 2 | 2020 | 1663 | 0.160 |
Why?
|
Ovarian Neoplasms | 1 | 2016 | 4904 | 0.160 |
Why?
|
Azetidines | 1 | 2020 | 151 | 0.160 |
Why?
|
Neoplasm Transplantation | 2 | 2013 | 2012 | 0.160 |
Why?
|
Pyridones | 1 | 2024 | 818 | 0.150 |
Why?
|
Quinazolinones | 1 | 2020 | 219 | 0.150 |
Why?
|
Aniline Compounds | 1 | 2024 | 1079 | 0.150 |
Why?
|
Integrin alpha5beta1 | 1 | 2018 | 36 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2018 | 10745 | 0.150 |
Why?
|
Administration, Oral | 4 | 2020 | 4018 | 0.150 |
Why?
|
Stromal Cells | 2 | 2001 | 1334 | 0.150 |
Why?
|
Positron-Emission Tomography | 3 | 2024 | 6550 | 0.150 |
Why?
|
Pyrrolidinones | 1 | 2018 | 116 | 0.140 |
Why?
|
Quinazolines | 2 | 2015 | 1367 | 0.140 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2020 | 296 | 0.140 |
Why?
|
Losartan | 1 | 2019 | 263 | 0.140 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 635 | 0.140 |
Why?
|
Pancreas | 3 | 2020 | 1698 | 0.140 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2017 | 92 | 0.140 |
Why?
|
Purines | 1 | 2020 | 615 | 0.140 |
Why?
|
Integrins | 1 | 2001 | 839 | 0.130 |
Why?
|
Wnt Proteins | 1 | 2020 | 722 | 0.130 |
Why?
|
Antigens, Surface | 1 | 2020 | 1617 | 0.130 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2020 | 2881 | 0.130 |
Why?
|
Peritoneal Neoplasms | 1 | 2022 | 706 | 0.120 |
Why?
|
Bone Marrow Purging | 1 | 1995 | 108 | 0.120 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2017 | 330 | 0.120 |
Why?
|
Vaccines | 1 | 2024 | 842 | 0.120 |
Why?
|
Feasibility Studies | 2 | 2023 | 5306 | 0.120 |
Why?
|
Ferrosoferric Oxide | 1 | 2016 | 349 | 0.120 |
Why?
|
Drug Interactions | 1 | 2019 | 1419 | 0.120 |
Why?
|
Platinum | 1 | 2016 | 219 | 0.120 |
Why?
|
Transplantation, Heterologous | 2 | 2013 | 2391 | 0.110 |
Why?
|
Retreatment | 1 | 2016 | 598 | 0.110 |
Why?
|
Hodgkin Disease | 1 | 2002 | 1384 | 0.110 |
Why?
|
Social Environment | 1 | 2019 | 1012 | 0.110 |
Why?
|
DNA, Neoplasm | 1 | 2019 | 1741 | 0.110 |
Why?
|
Sulfones | 2 | 2014 | 447 | 0.110 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 3944 | 0.110 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 627 | 0.110 |
Why?
|
Glycine | 2 | 2014 | 670 | 0.110 |
Why?
|
MAP Kinase Signaling System | 1 | 2020 | 1491 | 0.110 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 646 | 0.100 |
Why?
|
Biological Assay | 1 | 2016 | 626 | 0.100 |
Why?
|
Workplace | 1 | 2019 | 873 | 0.100 |
Why?
|
Mucin-1 | 1 | 2017 | 536 | 0.100 |
Why?
|
Pyrazines | 1 | 2018 | 1204 | 0.100 |
Why?
|
Receptors, CXCR | 1 | 2012 | 52 | 0.100 |
Why?
|
Imidazoles | 1 | 2018 | 1168 | 0.100 |
Why?
|
Mutation | 4 | 2024 | 30213 | 0.100 |
Why?
|
ras Proteins | 2 | 2017 | 1055 | 0.100 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2012 | 128 | 0.100 |
Why?
|
Radiosurgery | 1 | 2021 | 1329 | 0.090 |
Why?
|
Cell Line, Tumor | 4 | 2024 | 17088 | 0.090 |
Why?
|
Membrane Transport Proteins | 1 | 2017 | 1029 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2019 | 2056 | 0.090 |
Why?
|
Quality of Life | 5 | 2023 | 13476 | 0.090 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2018 | 1935 | 0.090 |
Why?
|
Cyclin D1 | 1 | 2012 | 454 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 4 | 2024 | 36567 | 0.090 |
Why?
|
Neoplasm Metastasis | 5 | 2020 | 4891 | 0.090 |
Why?
|
Thrombosis | 1 | 2023 | 2953 | 0.080 |
Why?
|
Disease Progression | 4 | 2022 | 13640 | 0.080 |
Why?
|
Patient Care Team | 1 | 2020 | 2519 | 0.080 |
Why?
|
Drug Synergism | 1 | 2013 | 1756 | 0.080 |
Why?
|
Tissue Distribution | 1 | 2013 | 2275 | 0.080 |
Why?
|
Young Adult | 6 | 2021 | 59939 | 0.080 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 904 | 0.080 |
Why?
|
Bone Marrow | 1 | 1998 | 2926 | 0.070 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 5387 | 0.070 |
Why?
|
Prognosis | 6 | 2022 | 29948 | 0.070 |
Why?
|
RNA Interference | 2 | 2017 | 2827 | 0.070 |
Why?
|
Cell Culture Techniques | 1 | 1995 | 1646 | 0.070 |
Why?
|
Autophagy | 1 | 2016 | 1346 | 0.070 |
Why?
|
Pancreatectomy | 2 | 2023 | 825 | 0.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3666 | 0.070 |
Why?
|
Retrospective Studies | 11 | 2023 | 81635 | 0.070 |
Why?
|
Drug Design | 1 | 2012 | 1042 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2012 | 996 | 0.070 |
Why?
|
Standard of Care | 2 | 2022 | 569 | 0.070 |
Why?
|
Tumor Cells, Cultured | 3 | 2001 | 6104 | 0.070 |
Why?
|
Proto-Oncogene Proteins | 3 | 2014 | 4522 | 0.070 |
Why?
|
Metabolome | 1 | 2013 | 1009 | 0.060 |
Why?
|
Energy Metabolism | 1 | 2017 | 2903 | 0.060 |
Why?
|
Glucose | 1 | 2017 | 4340 | 0.060 |
Why?
|
Cohort Studies | 6 | 2023 | 41710 | 0.060 |
Why?
|
Homozygote | 1 | 2010 | 1775 | 0.060 |
Why?
|
Registries | 1 | 2021 | 8351 | 0.060 |
Why?
|
Demography | 1 | 2010 | 1641 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5887 | 0.060 |
Why?
|
Signal Transduction | 5 | 2017 | 23619 | 0.060 |
Why?
|
Gallium Radioisotopes | 1 | 2024 | 195 | 0.060 |
Why?
|
Disease-Free Survival | 3 | 2017 | 6850 | 0.050 |
Why?
|
Radiopharmaceuticals | 2 | 2024 | 2704 | 0.050 |
Why?
|
Mesenteric Veins | 1 | 2023 | 87 | 0.050 |
Why?
|
RNA, Small Interfering | 1 | 2012 | 3425 | 0.050 |
Why?
|
Contrast Media | 1 | 2016 | 5329 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2022 | 2028 | 0.050 |
Why?
|
Cell Communication | 2 | 2001 | 1660 | 0.050 |
Why?
|
Cell Adhesion | 2 | 2017 | 3093 | 0.050 |
Why?
|
Carcinoembryonic Antigen | 1 | 2023 | 337 | 0.050 |
Why?
|
Chlorambucil | 1 | 2002 | 42 | 0.050 |
Why?
|
Survival Rate | 3 | 2022 | 12825 | 0.050 |
Why?
|
Procarbazine | 1 | 2002 | 172 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11061 | 0.050 |
Why?
|
Mice | 5 | 2024 | 81889 | 0.050 |
Why?
|
CA-19-9 Antigen | 1 | 2022 | 109 | 0.050 |
Why?
|
Combined Modality Therapy | 3 | 2022 | 8540 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3552 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2012 | 3511 | 0.050 |
Why?
|
Phosphorylation | 1 | 2012 | 8307 | 0.050 |
Why?
|
Azacitidine | 1 | 2022 | 335 | 0.050 |
Why?
|
Prednisolone | 1 | 2002 | 326 | 0.050 |
Why?
|
Bleomycin | 1 | 2002 | 492 | 0.050 |
Why?
|
Survival Analysis | 2 | 2012 | 10100 | 0.050 |
Why?
|
Integrin alpha4beta1 | 1 | 2001 | 119 | 0.040 |
Why?
|
Nitrates | 1 | 2022 | 260 | 0.040 |
Why?
|
GTP Phosphohydrolases | 1 | 2024 | 525 | 0.040 |
Why?
|
Portal Vein | 1 | 2023 | 437 | 0.040 |
Why?
|
Animals | 8 | 2024 | 168930 | 0.040 |
Why?
|
Vinblastine | 1 | 2002 | 482 | 0.040 |
Why?
|
Genes, MHC Class I | 1 | 2021 | 236 | 0.040 |
Why?
|
Hematologic Tests | 1 | 2021 | 239 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 329 | 0.040 |
Why?
|
Preoperative Period | 1 | 2022 | 564 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 784 | 0.040 |
Why?
|
Blood Loss, Surgical | 1 | 2023 | 642 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2016 | 8926 | 0.040 |
Why?
|
Edema | 1 | 2023 | 764 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2022 | 687 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 638 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2021 | 428 | 0.040 |
Why?
|
Plasma Membrane Calcium-Transporting ATPases | 1 | 2017 | 17 | 0.040 |
Why?
|
Fibrosis | 1 | 2024 | 2077 | 0.030 |
Why?
|
Pentose Phosphate Pathway | 1 | 2017 | 126 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2001 | 1337 | 0.030 |
Why?
|
Monocarboxylic Acid Transporters | 1 | 2017 | 81 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2021 | 20708 | 0.030 |
Why?
|
Carcinoma, Renal Cell | 1 | 2012 | 3186 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2019 | 1001 | 0.030 |
Why?
|
Digoxin | 1 | 2017 | 246 | 0.030 |
Why?
|
Age Factors | 2 | 2023 | 18397 | 0.030 |
Why?
|
Genetic Heterogeneity | 1 | 2019 | 735 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2024 | 1998 | 0.030 |
Why?
|
Autopsy | 1 | 2019 | 1011 | 0.030 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 891 | 0.030 |
Why?
|
Propensity Score | 1 | 2023 | 1972 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 787 | 0.030 |
Why?
|
Genotype | 1 | 2010 | 13036 | 0.030 |
Why?
|
Culture | 1 | 2019 | 622 | 0.030 |
Why?
|
Breast Neoplasms | 2 | 2020 | 21162 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2012 | 4282 | 0.030 |
Why?
|
Job Satisfaction | 1 | 2019 | 548 | 0.030 |
Why?
|
Doxorubicin | 1 | 2002 | 2229 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2020 | 1787 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 1002 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 9404 | 0.030 |
Why?
|
Radiotherapy | 1 | 2021 | 1497 | 0.030 |
Why?
|
Subcutaneous Fat | 1 | 2018 | 401 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2018 | 562 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2013 | 39309 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2021 | 2911 | 0.030 |
Why?
|
Carbon | 1 | 2017 | 673 | 0.030 |
Why?
|
Muscles | 1 | 2018 | 1576 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2019 | 2234 | 0.030 |
Why?
|
Organ Size | 1 | 2018 | 2261 | 0.030 |
Why?
|
Research | 1 | 2021 | 1977 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2001 | 3609 | 0.030 |
Why?
|
Glycosylphosphatidylinositols | 1 | 2012 | 88 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1594 | 0.030 |
Why?
|
Patient Participation | 1 | 2021 | 1445 | 0.020 |
Why?
|
Calcium Signaling | 1 | 2017 | 736 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2017 | 1168 | 0.020 |
Why?
|
Peptides | 1 | 2024 | 4344 | 0.020 |
Why?
|
Prospective Studies | 3 | 2021 | 54871 | 0.020 |
Why?
|
Cell Cycle Proteins | 2 | 2014 | 3439 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2012 | 125 | 0.020 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2017 | 794 | 0.020 |
Why?
|
Cell Division | 1 | 1998 | 4474 | 0.020 |
Why?
|
Tumor Burden | 1 | 2017 | 1900 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2016 | 1227 | 0.020 |
Why?
|
Amino Acids | 1 | 2017 | 1711 | 0.020 |
Why?
|
Medical Oncology | 1 | 2022 | 2340 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 16044 | 0.020 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2017 | 1319 | 0.020 |
Why?
|
Macaca fascicularis | 1 | 2012 | 908 | 0.020 |
Why?
|
Niacinamide | 1 | 2012 | 419 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4114 | 0.020 |
Why?
|
Lymphopenia | 1 | 2012 | 299 | 0.020 |
Why?
|
Hydroxamic Acids | 1 | 2012 | 483 | 0.020 |
Why?
|
Transfection | 1 | 2017 | 5754 | 0.020 |
Why?
|
Cell Survival | 1 | 1998 | 5748 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6779 | 0.020 |
Why?
|
DNA Methylation | 1 | 2022 | 4427 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1394 | 0.020 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1995 | 1374 | 0.020 |
Why?
|
United States | 3 | 2021 | 72951 | 0.020 |
Why?
|
Area Under Curve | 1 | 2012 | 1638 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2012 | 13485 | 0.020 |
Why?
|
Time Factors | 2 | 2021 | 40149 | 0.020 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2012 | 776 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6512 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2022 | 14652 | 0.020 |
Why?
|
Neutropenia | 1 | 2012 | 894 | 0.020 |
Why?
|
Disease Management | 1 | 2017 | 2533 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2022 | 9525 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3236 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4747 | 0.020 |
Why?
|
Health Personnel | 1 | 2019 | 3384 | 0.020 |
Why?
|
Thalidomide | 1 | 2010 | 886 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10619 | 0.020 |
Why?
|
Pyrimidines | 1 | 2017 | 3043 | 0.010 |
Why?
|
Cell Movement | 1 | 2017 | 5199 | 0.010 |
Why?
|
Fatigue | 1 | 2012 | 1555 | 0.010 |
Why?
|
Protein Binding | 1 | 2017 | 9320 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 8045 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15416 | 0.010 |
Why?
|
Risk Factors | 2 | 2020 | 74881 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12064 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14762 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2014 | 3721 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 21525 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2017 | 12534 | 0.010 |
Why?
|
Logistic Models | 1 | 2017 | 13278 | 0.010 |
Why?
|
Apoptosis | 1 | 1998 | 9513 | 0.010 |
Why?
|
Computer Simulation | 1 | 2016 | 6259 | 0.010 |
Why?
|
Databases, Factual | 1 | 2017 | 8066 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2017 | 10445 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2017 | 8621 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 18075 | 0.010 |
Why?
|